2021-11-14T18:47:28-06:00 2020-12-31 BDO USA LLP 8401 GREENSBORO DRIVE 800 MCLEAN VA 22102 990 2020-01-01 136180380 AMERICAN SOCIETY OF CLINICAL ONCOLOGY INC % LINDA JENSEN CFO AMER 5714831300 2318 MILL ROAD Suite 800 ALEXANDRIA VA 22314 LINDA JENSEN CFO 5714831300 2021-11-10 true LINDA JENSEN 999009999 Marc Berger P01871563 7038930600 2 2020 2022-09-23 18:48:47Z CLIFFORD HUDIS MD CEO 2318 MILL ROAD 800 ALEXANDRIA VA 22314 271160600 false X WWW.ASCO.ORG X 1965 NY ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, AND PROMOTION OF THE HIGHEST QUALITY, EQUITABLE PATIENT CARE. 19 19 541 3156 23003725 9881127 7525300 6446971 145628204 121740555 6514346 -4680218 3043571 14866774 162711421 138374082 2492264 7819588 0 0 61964764 58815087 0 0 0 83651841 68101126 148108869 134735801 14602552 3638281 269484782 279249289 131909947 119295053 137574835 159954236 X SEE SCHEDULE O false false 38236030 268 22561252 QUALITY OF CARE: SEE SCHEDULE O 31218356 21821 59468487 SCIENTIFIC AND MEDICAL EDUCATION: SEE SCHEDULE O 16277341 57500 27607091 SCIENTIFIC PUBLICATIONS: SEE SCHEDULE O 34305302 7739998 12103725 120037029 true true false true false false false false false false true false false false true true false true false true true true false false false false false true false true true false false false false false false false false false false false false false false true true true true true false true 330 0 true 541 true true true false false false false false false false false false false false X 19 19 false false false false true true true true true false false true true true true true true true true false CA NY VA X LINDA JENSEN CFO 5714831300 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 X Clifford Hudis MD Chief Executive Officer 30.0 8.0 X 950644 0 21375 Dina Michels Esq Secretary, EVP & CLPO 30.0 8.0 X 630317 0 38827 Richard Schilsky MD EVP & Chief Medical Officer 38.0 0.0 X 632010 0 27935 Cory Wiegert EVP & CEO, CancerLinQ 38.0 0.0 X 527348 0 36760 Christopher Merlan EVP & Chief Digital Officer 38.0 0.0 X 457231 0 45501 Linda Jensen CPA EVP and CFO 30.0 8.0 X 432564 0 38827 Jamie Von Roenn MD VP, Edu., Science & Prof. Dev. 38.0 0.0 X 426291 0 35960 Stephen Grubbs MD Vice President, Care Delivery 19.0 19.0 X 422920 0 37962 Bernie Khoo Former VP Info. Technology 38.0 0.0 X 456272 0 0 Nancy Daly MS MPH EVP & CEO CONQUER CANCER FDN 3.0 35.0 X 412571 0 41796 Robert Miller MD Medical Director, CancerLinQ 38.0 0.0 X 389271 0 48992 Carmen Jackson Chief of Operations, CLQ 38.0 0.0 X 366493 0 45501 Deborah Kamin RNPhD VP, Policy & Advocacy 19.0 19.0 X 326336 0 41796 Kristin Ludwig VP, Marketing & Communications 38.0 0.0 X 329970 0 21375 Anil Nair Chief Technology Officer, CLQ 38.0 0.0 X 293972 0 36003 Krista Barnes Former VP Member Services 19.0 19.0 X 0 271557 44347 Carolyn Whitehead Div. Dir., Philantrophy, CC 1.0 37.0 X 290860 0 21375 Amanda Davis-Aitken Vice President, Meeting SVCS 38.0 0.0 X 277055 0 28209 Barton Lawyer Vice President - IT 38.0 0.0 X 214158 0 36418 Howard A Burris III MD PAST PRESIDENT/CHAIR 1.0 2.0 X X 0 0 0 Lori J Pierce MD PRESIDENT-ELECT/PRESIDENT 1.0 1.0 X X 0 0 0 Monica M Bertagnolli MD CHAIR AND PAST PRESIDENT 1.0 1.0 X X 0 0 0 Laurie E Gaspar MD MBA TREASURER 1.0 1.0 X X 0 0 0 Everett E Vokes MD ASCO PRESIDENT-ELECT 1.0 1.0 X X 0 0 0 Peter C Adamson MD Board Member 1.0 1.0 X 0 0 0 Ethan M Basch MD Board Member 1.0 0.0 X 0 0 0 A William Blackstock MD Board Member 1.0 0.0 X 0 0 0 Lisa A Carey MD Board Member 1.0 0.0 X 0 0 0 Enrique Soto Perez de Celis Board Member 1.0 0.0 X 0 0 0 Lee M Ellis MD Board Member 1.0 0.0 X 0 0 0 Tara O Henderson MD MPH Board Member 1.0 0.0 X 0 0 0 Maha H A Hussain MD Board Member 1.0 1.0 X 0 0 0 Reshma Jagsi MD Board Member 1.0 1.0 X 0 0 0 Michael P Kosty MD Board Member 1.0 1.0 X 0 0 0 Elizabeth A Mittendorf MD Board Member 1.0 0.0 X 0 0 0 Tony S K Mok BMSc MD Board Member 1.0 0.0 X 0 0 0 Elizabeth R Plimack MD MS Board Member 1.0 0.0 X 0 0 0 Blase N Polite MD MPP Board Member 1.0 1.0 X 0 0 0 Eric J Small MD Board Member 1.0 1.0 X 0 0 0 Michael A Thompson MD PhD Board Member 1.0 0.0 X 0 0 0 Jaap Verweij MD PhD Board Member 1.0 1.0 X 0 0 0 Tracey F Weisberg MD Board Member 1.0 0.0 X 0 0 0 7836283 271557 648959 237 true true false Tempus Labs LLC 600 West Chicago Ave CHICAGO IL 60654 Data Curation 6338121 Spargo 11208 Waples Mill Road 112 FAIRFAX VA 22030 Event Management 4656773 Concerto Health AI Solutions LLC 501 Boylston St BOSTON MA 02116 Data Technology 4519147 Publicis Sapient 1515 North Courthouse Road 4th Flo ARLINGTON VA 22201 Dig. Transformation 4200639 Dartmouth Printing Company 69 Lyme Road HANOVER NH 03755 Printing Service 2297247 96 6418295 28676 6446971 EDUCATIONAL MEETINGS AND FEES 900099 65391550 59468487 5923063 QUALITY OF CARE 900099 22561251 22561251 SCIENTIFIC PUBLICATIONS 511190 21684029 4603861 17080168 DUES 900099 6606544 6606544 MEMBER RELATIONS & INFORMATION 900099 3080859 3080859 2416322 2416322 121740555 3373510 3373510 0 14866280 14866280 8266 7772 494 0 494 494 124725018 0 132724721 54025 -7999703 -54025 -8053728 -8053728 0 0 0 0 0 0 0 0 0 0 138374082 98737324 23003725 10186062 X 7766588 7766588 0 53000 53000 0 6031274 3796679 2234595 0 39081222 32882569 6198653 3901584 3199299 702285 5648463 4649823 998640 4152544 3405086 747458 0 410342 300054 110288 142394 142394 0 0 60809 60809 20222369 19905854 316515 0 598547 488140 110407 1208158 724568 483590 8186316 6756540 1429776 0 6594187 5981343 612844 1992645 1918272 74373 0 11474792 11370770 104022 0 0 3311592 3013549 298043 698690 635808 62882 PRINTING & PRODUCTION 8237795 8226597 11198 UBI TAX 3321434 3321434 BAD DEBT 827052 827052 OTHER 814004 814004 134735801 120037029 14698772 0 0 0 18722737 19356599 0 0 26850085 26710378 0 0 0 0 0 5600000 0 0 7946486 5424995 80676944 31719973 48134749 48956971 167830725 173200346 0 0 0 0 0 0 0 0 269484782 279249289 18849700 10180370 0 0 37609894 38354168 38400000 38400000 0 0 0 0 0 15345000 0 0 37050353 17015515 131909947 119295053 X 136574835 159229656 1000000 724580 137574835 159954236 269484782 279249289 X 3638281 10350623 8390497 X false true X true false X 11941446 9978694 8575801 7525300 6446971 44468212 78719498 93297144 136574903 123116955 98737324 530445824 0 0 0 90660944 103275838 145150704 130642255 105184295 574914036 0 0 0 574914036 5651063 5969247 7763043 8610595 18248056 46242004 0 5651063 5969247 7763043 8610595 18248056 46242004 3414649 2871782 4855029 7776132 8302393 27219985 277776 248859 255345 251085 0 1033065 100004432 112365726 158024121 147280067 131734744 649409090 0.88529 0.82663 0.07121 0.05456 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 120037029 120037029 1000000 250000 1000000 1000000 1000000 1000000 4000000 6000000 291378 198306 439604 0 929288 250000 250000 250000 250000 1000000 1500000 2905 1947 263 0 5115 7342677 7342677 46941779 15044509 31897270 780214 774006 6208 4854156 3432354 1421802 20758117 12469103 8289014 48956971 0 LIABILITY UNDER INTEREST RATE SWAP 16154445 DUE TO RELATED ORGANIZATION 861070 17015515 X PART X, LINE 2: IN ACCORDANCE WITH GAAP, THE ORGANIZATION MAY RECOGNIZE THE TAX BENEFIT FROM AN UNCERTAIN TAX POSITION ONLY IF IT IS MORE LIKELY THAN NOT THAT THE TAX POSITION WILL BE SUSTAINED ON EXAMINATION BY TAXING AUTHORITIES, BASED ON TECHNICAL MERITS OF THE POSITION. THE TAX BENEFITS RECOGNIZED IN THE CONSOLIDATED FINANCIAL STATEMENTS FROM SUCH A POSITION ARE MEASURED BASED ON THE LARGEST BENEFIT THAT HAS A GREATER THAN 50% LIKELIHOOD OF BEING REALIZED UPON ULTIMATE SETTLEMENT. THE ORGANIZATION BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR TAX POSITIONS TAKEN, AND THEREFORE, DOES NOT HAVE UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE CONSOLIDATED FINANCIAL STATEMENTS. GENERALLY, THE ORGANIZATION IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS BY THE U.S. FEDERAL, STATE OR LOCAL TAX AUTHORITIES FOR YEARS PRIOR TO DECEMBER 31, 2017. true Middle East and North Africa Program Services Outreach & Educational 11963 Russia and the Newly Independent States Program Services OUTREACH & EDUCATIONAL 1000 South Asia Program Services Outreach & Educational 34953 Europe (Including Iceland and Greenland) Grantmaking 53000 100916 100916 Europe (Including Iceland and Greenland) Contribution 53000 WIRE 1 false false false false false true SCHEDULE F, PART I, LINE 2 ASCO provided assistance to international organizations that serve the cancer community. In 2020, ASCO's international donation was to a European non-government organization that supports cities around the world as they work to improve access to equitable, quality cancer care and transforms the way stakeholders collectively design, plan, and implement cancer solutions. true Conquer Cancer Foundation of ASCO 2318 Mill Road Alexandria VA 22314 311667995 501(c)(3) 7262500 Contribution Sarah Cannon Research Institute One Park Plaza Nashville TN 32703 201557751 LLC 130000 Contribution Regents of the University of Michigan 300 N Ingalls St Ann Arbor MI 48109 386006309 501(C)(3) 109167 contribution Brigham & Women's Hospital 75 Francis St Tower 1 Boston MA 02215 042312909 501(C)(3) 89167 Contribution Banner Health 2901 N Central Ave Phoenix AZ 85012 450233470 501(C)(3) 60000 Contribution University of Chicago Medical Center 5841 S Maryland Ave Chicago IL 60637 363488183 501(c)(3) 46667 Contribution Friends of Cancer Research 1800 M Street Washington DC 20036 521983273 501(c)(3) 22000 Contribution Health Volunteers Overseas 1900 L Street NW Washington DC 20036 521485477 501(c)(3) 10000 Contribution Association of American Cancer Institutes 3708 Fifth Ave Pittsburgh PA 15213 237410581 501(c)(3) 10000 Contribution National Coalition For Cancer Survivorship 8455 Colesville Rd Silver Spring MD 20910 850357897 501(c)(3) 10000 Contribution 9 1 SCHEDULE I, PART I, LINE 1: ASCO PROVIDES ASSISTANCE TO 501(C)(3) ORGANIZATIONS THAT SERVE THE CANCER COMMUNITY. SCHEDULE I, PART I, LINE 2: ASCO PROVIDES ASSISTANCE TO ORGANIZATIONS THAT SERVE THE CANCER CARE COMMUNITY. THE MAJORITY OF THESE GRANTS ARE MADE TO OTHER 501(C)(3) ORGANIZATIONS. THE GRANT MADE TO A NON-501(C)(3) ORGANIZATION WAS MADE PURSUANT TO A WRITTEN AGREEMENT THAT REQUIRED THE GRANT FUNDS TO BE USED FOR SPECIFIC EDUCATIONAL AND CHARITABLE PROJECTS, THAT THE GRANTEE RETURN ANY PORTION OF THE GRANT FUNDS THAT WERE NOT USED FOR SUCH PROJECTS, AND THAT THE GRANTEE PROVIDE ANNUAL NARRATIVE AND FINANCIAL REPORTS TO ASCO REGARDING GRANTEE'S USE OF THE GRANT FUNDS. X X X X X true false false false false false false true false Clifford Hudis MD Chief Executive Officer 876885 0 73759 0 0 0 21375 0 0 0 972019 0 0 0 Dina Michels Esq Secretary, EVP & CLPO 615317 0 15000 0 0 0 21375 0 17452 0 669144 0 0 0 Richard Schilsky MD EVP & Chief Medical Officer 612010 0 20000 0 0 0 21375 0 6560 0 659945 0 0 0 Cory Wiegert EVP & CEO, CancerLinQ 442348 0 85000 0 0 0 21375 0 15385 0 564108 0 0 0 Christopher Merlan EVP & Chief Digital Officer 437231 0 20000 0 0 0 21375 0 24126 0 502732 0 0 0 Linda Jensen CPA EVP and CFO 422564 0 10000 0 0 0 21375 0 17452 0 471391 0 0 0 Nancy Daly MS MPH EVP & CEO CONQUER CANCER FDN 402571 0 10000 0 0 0 21375 0 20421 0 454367 0 0 0 Amanda Davis-Aitken Vice President, Meeting SVCS 269055 0 8000 0 0 0 20221 0 7988 0 305264 0 0 0 Bernie Khoo Former VP Info. Technology 16346 0 0 0 439926 0 0 0 0 0 456272 0 0 0 Kristin Ludwig VP, Marketing & Communications 321970 0 8000 0 0 0 21375 0 0 0 351345 0 0 0 Stephen Grubbs MD Vice President, Care Delivery 414920 0 8000 0 0 0 21375 0 16587 0 460882 0 0 0 Jamie Von Roenn MD VP, Edu., Science & Prof. Dev. 418291 0 8000 0 0 0 21375 0 14585 0 462251 0 0 0 Robert Miller MD Medical Director, CancerLinQ 371421 0 17850 0 0 0 21375 0 27617 0 438263 0 0 0 Carmen Jackson Chief of Operations, CLQ 366493 0 0 0 0 0 21375 0 24126 0 411994 0 0 0 Deborah Kamin RNPhD VP, Policy & Advocacy 318336 0 8000 0 0 0 21375 0 20421 0 368132 0 0 0 Carolyn Whitehead Div. Dir., Philantrophy, CC 285860 0 5000 0 0 0 21375 0 0 0 312235 0 0 0 Anil Nair Chief Technology Officer, CLQ 293972 0 0 0 0 0 20647 0 15356 0 329975 0 0 0 Barton Lawyer Vice President - IT 209158 0 5000 0 0 0 16036 0 20382 0 250576 0 0 0 Krista Barnes Former VP Member Services 0 263557 0 8000 0 0 0 20221 0 24126 0 315904 0 0 PART I, LINE 4A: BERNIE KHOO, FORMER VICE PRESIDENT INTEGRATED MEDIA, RECEIVED SEVERANCE OF $439,926 IN 2020. PART I, LINE 7: THE ORGANIZATION HAS A DISCRETIONARY BONUS PLAN UNDER WHICH SELECTED EMPLOYEES, INCLUDING OFFICERS, KEY EMPLOYEES AND OTHER EMPLOYEES ARE COMPENSATED BASED ON PERFORMANCE AND THE ACHIEVEMENT OF SPECIFIC PROFESSIONAL GOALS. BONUSES FOR KEY EMPLOYEES AND HIGHEST COMPENSATED EMPLOYEES ARE APPROVED BY THE CEO WITH REVIEW AND APPROVAL BY THE COMPENSATION COMMITTEE OF THE BOARD, WHERE APPROPRIATE. A INDUSTRIAL DEVELOPMENT AUTHORITYCITY OF ALEXANDRI 521381432 01530LAD2 2012-08-01 38400000 Buy/Buildout 5 floors HQ building false false false A 0 0 38400000 0 0 0 0 0 0 38400000 0 0 2008 true false true true A false false true true false 0 0.03980 0.03980 false false false true A false false false true true true FMS WERTMANAGEMENT 30. false false false 0 false true A true PART IV, QUESTION 3 ASCO HAS AN INTEREST RATE SWAP AGREEMENT WITH FMS WERTMANAGEMENTBANK THROUGH 2038. ASCO MAKES FIXED INTEREST PAYMENTS AT A 3.587% RATE. VARIABLE SWAP PAYMENTS, BASED ON ONE-MONTH LIBOR, RECEIVED FROM THE SWAP COUNTERPARTY ARE USED TO MAKE THE VARIABLE INTEREST PAYMENTS AS THEY COME DUE. THIS INTEREST RATE SWAP AGREEMENT QUALIFIES AS A DERIVATIVE INSTRUMENT AND IS USED TO MITIGATE THE EFFECT OF INTEREST RATE FLUCTUATIONS. PART VI, QUESTION 2C THE LATEST REBATE COMPUTATION DATE FOR THE REPORTED BOND ISSUE WAS SEPTEMBER 29, 2020. FORM 990, PART III, LINE 1: ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, AND PROMOTION OF THE HIGHEST QUALITY, EQUITABLE PATIENT CARE. ASCO'S VISION IS A WORLD WHERE CANCER IS PREVENTED OR CURED, AND EVERY SURVIVOR IS HEALTHY. ASCO PROMOTES AND PROVIDES FOR: - LIFELONG LEARNING FOR ONCOLOGY PROFESSIONALS, - CANCER RESEARCH, - AN IMPROVED ENVIRONMENT FOR ONCOLOGY PRACTICE, - ACCESS TO QUALITY CANCER CARE, - A GLOBAL NETWORK OF ONCOLOGY EXPERTISE, AND - EDUCATED AND INFORMED PATIENTS WITH CANCER. FORM 990, PART III, LINE 4A: QUALITY OF CARE: ASCO, THROUGH COLLECTION OF ONCOLOGY PRACTICE CARE DELIVERY METRICS, DEVELOPS INSIGHTS TO IMPROVE THE QUALITY AND EQUITY OF ONCOLOGY CARE DELIVERY. ASCO ALSO PRODUCES EVIDENCE-BASED GUIDELINES, QUALITY MEASURES AND DEVELOPS STANDARDS FOR QUALITY ONCOLOGY CARE, AND PROVIDES TRAINING IN QUALITY CARE DELIVERY. CANCERLINQ'S BIG-DATA PLATFORM DELIVERS VALUABLE INSIGHTS AND TOOLS TO PARTICIPATING PRACTICES AND DE-IDENTIFIED DATA FOR CANCER TREATMENT RESEARCH. THE CANCERLINQ DATABASE, which includes information from millions of cancer patient care records, reflects cancer care in ALL ITS REAL-WORLD VARIABILITY, ALLOWING CLINICIANS TO LEARN FROM THE EXPERIENCE OF EVERY PATIENT. QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI). A QUALITY ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES: QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICE STAFF TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3) COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. QUALITY TRAINING PROGRAM. ASCO'S QUALITY TRAINING PROGRAM IS DESIGNED TO HELP PRACTICES IMPROVE CLINICAL CARE AND OPERATIONAL PERFORMANCE. FORM 990, PART III, LINE 4B: SCIENTIFIC AND MEDICAL EDUCATION: ASCO PROVIDES SCIENTIFIC AND EDUCATIONAL PROGRAMS AND CONTENT ON A BROAD RANGE OF ONCOLOGY-RELATED TOPICS IN A VARIETY OF FORMATS. WORKING WITH VOLUNTEER ASCO MEMBERS, ASCO ORDINARILY PLANS AND PRESENTS LIVE MEETINGS ON THE LATEST RESEARCH AND ADVANCES IN THE FIELD OF CLINICAL ONCOLOGY. DUE TO THE COVID-19 PANDEMIC, ASCO'S MEETINGS SCHEDULED AFTER MARCH 2020, INCLUDING ITS ANNUAL MEETING, WERE HELD VIRTUALLY WITH ATTENDEES FROM AROUND THE WORLD VIEWING ONCOLOGY-SPECIFIC INFORMATION. THE ATTENDEES PARTICIPATE TO ENHANCE THEIR KNOWLEDGE ABOUT TREATING CANCER AND CARING FOR CANCER PATIENTS. ASCO ANNUAL MEETING IS THE WORLD'S PREMIER SCIENTIFIC AND EDUCATIONAL MEETING IN THE ONCOLOGY COMMUNITY. IN ADDITION, ASCO SPONSORS OR CO-SPONSORS THEMATIC MEETINGS (FOCUSING ON SUBSPECIALTY AREAS), WHICH PROVIDE OPPORTUNITIES FOR FOCUSED EDUCATIONAL AND SCIENTIFIC SESSIONS ON SPECIFIC TYPES OF CANCERS. ASCO'S PROGRAMS ARE DESIGNED TO SERVE THE DIVERSE NEEDS OF ONCOLOGY PRACTITIONERS WORLDWIDE, ASSISTING THEM IN DELIVERING HIGH QUALITY CANCER CARE AND CONDUCTING CLINICAL RESEARCH THROUGH THE CONTINUUM OF THEIR CAREERS. PROGRAMS ADDRESS THE MODERN-DAY PRACTICE OF ONCOLOGY FOR ALL LEVELS OF PRACTITIONERS INCLUDING ONCOLOGY FELLOWS, JUNIOR FACULTY MEMBERS, ONCOLOGY PROGRAM DIRECTORS, ETC. HIGHLIGHTS OF THE 2020 VIRTUAL ANNUAL MEETING INCLUDE OVER 5,000 ABSTRACTS WERE PRESENTED OR PUBLISHED, NEARLY 5,000 PRESENTATIONS WERE CAPTURED IN VIDEO, WITH OVER 42,500 ATTENDEES. THE GASTROINTESTINAL CANCERS AND THE GENITOURINARY CANCERS SYMPOSIA COVERED 1,920 ABSTRACTS FOR 8,525 ATTENDEES. CONTENT IS MAINTAINED DIGITALLY AND MADE ACCESSIBLE. COVERAGE OF THE MEETINGS' CONTENT IS PUBLISHED IN A NEWS PRODUCT DISTRIBUTED DAILY DURING THE MEETINGS AND AVAILABLE ON ASCO'S WEBSITES, COVERED IN PODCASTS, AND PUBLIC FORUMS. WORKING WITH VOLUNTEER ASCO MEMBERS, ASCO PLANS, DEVELOPS, DELIVERS, AND EVALUATES CONTINUING MEDICAL EDUCATION (CME) COURSES TO SUPPORT THE CONTINUED EDUCATION OF ONCOLOGISTS AND OTHER MEMBERS OF THE CANCER CARE TEAM TO ENABLE THEM TO BETTER MEET THE PREVENTION, DIAGNOSIS AND TREATMENT NEEDS OF THEIR PATIENTS. CURRENTLY, ASCO HOLDS THE STATUS OF ACCREDITATION WITH COMMENDATION FROM THE ACCREDITATION COUNCIL FOR CONTINUING MEDICAL EDUCATION. DURING 2020, 182,484 CONTINUING MEDICAL EDUCATION (CME)CREDITS WERE AWARDED TO PARTICIPANTS IN ASCO EDUCATIONAL ACTIVITIES. MANY ADDITIONAL ONCOLOGY CARE PROVIDERS ENROLLED IN COURSES WITHOUT RECEIVING CME. IN ADDITION, ASCO PROVIDES WORKSHOPS ON CANCER RESEARCH, DELIVERY OF CARE, AND OTHER TOPICS, AS WELL AS ONCOLOGY EDUCATION TO NON-PHYSICIAN PROFESSIONALS WORKING IN THE FIELD OF ONCOLOGY. FORM 990, PART III, LINE 4C: SCIENTIFIC PUBLICATIONS: ASCO PRODUCES A NUMBER OF PROFESSIONAL PUBLICATIONS AND GENERAL PUBLICATIONS FOCUSED ON CLINICAL ONCOLOGY. O ASCO PUBLISHES HIGH-QUALITY, PEER-REVIEWED SCIENTIFIC PAPERS IN ITS JOURNALS: O JOURNAL OF CLINICAL ONCOLOGY (JCO) IS A HIGHLY REGARDED JOURNAL PUBLISHING SCIENTIFIC MANUSCRIPTS AND ARTICLES ON SIGNIFICANT CLINICAL ONCOLOGY RESEARCH IN PRINT AND ELECTRONIC FORMATS. O JCO ONCOLOGY PRACTICE (JCO OP) EDITED BY ONCOLOGISTS, JCO OP PRINTS ORIGINAL RESEARCH AND PERSPECTIVES ON CLINICAL AND ADMINISTRATIVE MANAGEMENT ADDRESSING THE PRACTICE OF ONCOLOGY. O JCO GLOBAL ONCOLOGY (JCO GO) AN ONLINE ONLY, OPEN ACCESS JOURNAL FOCUSES ON CANCER CARE, RESEARCH, AND CARE DELIVERY ISSUES UNIQUE TO COUNTRIES AND SETTINGS WITH LIMITED HEALTHCARE RESOURCES. O JCO CLINICAL CANCER INFORMATICS (JCO CCI) AN ONLINE-ONLY INTERDISCIPLINARY JOURNAL PUBLISHES CLINICALLY RELEVANT RESEARCH BASED ON BIOMEDICAL INFORMATICS METHODS AND PROCESSES APPLIED TO CANCER-RELATED DATA, INFORMATION, AND IMAGES. O JCO PRECISION ONCOLOGY (JCO PO) AN ONLINE-ONLY, ARTICLE-BASED JOURNAL PUBLISHING ORIGINAL RESEARCH, REPORTS, OPINIONS, AND REVIEWS THAT ADVANCE THE SCIENCE AND PRACTICE OF PRECISION ONCOLOGY AND DEFINES GENOMICS-DRIVEN CLINICAL CARE OF PATIENTS WITH CANCER. ASCO PUBLISHES THE ANNUAL CLINICAL CANCER ADVANCES (CCA) REPORT. THIS PUBLICLY AVAILABLE REPORT ESTABLISHES THE MOST IMPORTANT CLINICAL ADVANCES IN ONCOLOGY EACH YEAR. THE REPORT SERVES TO DOCUMENT THE PROGRESS BEING MADE AGAINST CANCER THROUGH CLINICAL RESEARCH, PARTICULARLY THROUGH FEDERALLY FUNDED RESEARCH. ASCO PROVIDES CONTENT AND DISTRIBUTION LISTS FOR TRADE PUBLICATIONS. WHILE NOT OWNED OR PUBLISHED BY ASCO, THE PUBLICATIONS COVER NEWS AND INFORMATION OF INTEREST TO THE PROFESSIONAL ONCOLOGY COMMUNITY. FORM 990, PART III, LINE 4D: 1. MEMBER SERVICES: ASCO works to support and educate its more than 45,000 members, in collaboration with its affiliate ASCO Association, d/b/a Association for Clinical Oncology (Association). ASCO and the Association have reciprocal membership, meaning that each member is a member of both ASCO and the Association. ASCO'S MEMBERS VOLUNTEER TO PROVIDE EXPERTISE FOR EDUCATION, PRACTICE GUIDELINES, POLICY, AND OTHER ONCOLOGY LEADERSHIP ACTIVITIES. EXPENSES $3,698,763. INCLUDING GRANTS OF $0. REVENUE $9,687,403. 2. RESEARCH: ASCO IS ACTIVELY ENGAGED IN THE SUPPORT, PROMOTION AND CONDUCT OF CLINICAL CANCER RESEARCH. RESEARCH RELATED ACTIVITIES INCLUDE: O ORIGINAL RESEARCH: ASCO CONDUCTS RESEARCH TO DEVELOP EVIDENCE THAT INFORMS PATIENT CARE, PUBLIC POLICY, AND EDUCATION. RESEARCH INCLUDES SURVEYS, OBSERVATIONAL STUDIES AND CLINICAL TRIALS. ITS MAJOR CLINICAL TRIAL, TAPUR, IS TESTING THE SAFETY AND EFFICACY OF FDA-APPROVED, TARGETED ANTI-CANCER THERAPIES IN OTHER CANCER TYPES FOR PATIENTS WITH AN INDICATIVE GENOMIC ALTERATION. IN 2020, ASCO LAUNCHED A REGISTRY TO COLLECT AND ANALYZE THE IMPACT OF COVID-19 ON CANCER PATIENT OUTCOMES. O SCIENTIFIC/RESEARCH COLLABORATIONS: ASCO WORKS WITH OTHER STAKEHOLDERS IN THE COMMUNITY, INCLUDING GOVERNMENT AGENCIES, PATIENT ADVOCACY GROUPS, AND OTHER PROFESSIONAL MEDICAL SOCIETIES TO SUPPORT AND PROMOTE RESEARCH THAT INFORMS EVIDENCE-BASED PATIENT CARE. THIS INCLUDES AN ASCO-FDA COLLABORATION TO JOINTLY HOST PUBLIC WORKSHOPS ON EMERGING ISSUES IN RESEARCH AND FDA REVIEW OF NEW THERAPIES. O RESEARCH GRANTS AND AWARDS: ASCO MAKES GRANTS TO its 501(c)(3) affiliated organization, CONQUER CANCER FOUNDATION OF the American Society of Clinical Oncology (Conquer Cancer) TO FUND COMPETITIVELY AWARDED RESEARCH GRANTS AND AWARDS. MOST OF THE GRANTS SUPPORT THE INDEPENDENT RESEARCH INITIATIVES OF CLINICAL INVESTIGATORS. EXPENSES $17,658,460. INCLUDING GRANTS OF $7,734,953. REVENUE $2,416,322. 3. CANCER POLICY: ASCO'S POLICY WORK FOCUSES ON THE ISSUES OF ACCESS TO AND DELIVERY OF HIGH-QUALITY AND EQUITABLE CANCER CARE FOR CANCER PATIENTS. WORKING WITH VOLUNTEER ASCO MEMBERS, THE SOCIETY DEVELOPS POSITIONS ADDRESSING ISSUES OF CRITICAL IMPORTANCE TO THE PRACTICE OF ONCOLOGY AND PATIENT CARE. ASCO'S POLICY PROGRAMS COVER A BROAD SPECTRUM OF ISSUES, INCLUDING CLINICAL CANCER RESEARCH, HEALTH INSURANCE, CLINICAL PRACTICE, WORKFORCE, DISPARITIES, COST/ACCESS, CANCER SURVIVORSHIP, AND CANCER PREVENTION AND CONTROL. ASCO PROVIDES EDUCATIONAL WORKSHOPS AND MATERIALS, LEGAL ANALYSIS, DEVELOPMENT OF FORMAL COMMENTS AND TESTIMONY, AND SPECIAL STUDIES ON CRITICAL ISSUES FOR THE CANCER COMMUNITY. ASCO ROUTINELY COLLABORATES WITH OTHERS IN THE COMMUNITY TO ADVANCE COMMON GOALS RELATED TO ACCESS TO AND DELIVERY OF HIGH-QUALITY CANCER CARE. EXPENSES $4,542,905. INCLUDING GRANTS OF $0. REVENUE $0. 4. PATIENT INFORMATION & OTHER: ASCO PROVIDES IMPORTANT INFORMATION TO THE PUBLIC FREE OF CHARGE THROUGH ITS AWARD-WINNING PATIENT EDUCATION WEBSITE, CANCER.NET (WWW.CANCER.NET), THROUGH A MOBILE APPLICATION, AND PATIENT EDUCATION MATERIALS. CANCER.NET BRINGS THE EXPERTISE AND RESOURCES OF ASCO TO PEOPLE LIVING WITH CANCER AND THOSE WHO CARE FOR AND CARE ABOUT THEM. CANCER.NET PROVIDES ONCOLOGIST-APPROVED INFORMATION TO HELP PATIENTS AND FAMILIES MAKE INFORMED HEALTH CARE DECISIONS. THE SITE OFFERS COMPREHENSIVE GUIDES TO MORE THAN 120 TYPES OF CANCER AND CANCER-RELATED SYNDROMES, INCLUDING DISEASE-SPECIFIC TREATMENT AND SIDE EFFECTS INFORMATION. EXTENSIVE INFORMATION CAN BE FOUND ON NAVIGATING CANCER CARE, COPING WITH CANCER, CLINICAL TRIALS, MANAGING SIDE EFFECTS, CAREGIVING, SURVIVORSHIP, AND RESEARCH AND ADVOCACY; SELECT CONTENT IS AVAILABLE IN SPANISH. CANCER.NET ALSO FEATURES VIDEOS, PODCASTS, AND AN AWARD-WINNING BLOG. EXPENSES $8,405,175. INCLUDING GRANTS OF $5,045. REVENUE $0. FORM 990, PART VI, SECTION A, LINE 1: AS OF DECEMBER 31, 2020, THE BOARD OF DIRECTORS OF ASCO INCLUDED 19 MEMBERS WITH THE RIGHT TO VOTE ON ALL MATTERS THAT COME BEFORE THE BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES TWO EX-OFFICIO DIRECTORS WITHOUT THE RIGHT TO VOTE, WHO ARE THE CHIEF EXECUTIVE OFFICER OF ASCO (CEO) AND THE CHAIR OF THE BOARD OF DIRECTORS OF CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (A NON-PROFIT, 501(C)(3) TAX-EXEMPT RELATED ORGANIZATION OF ASCO). DURING THE REPORTING YEAR, THE BOARD OF DIRECTORS DELEGATED AUTHORITY TO ACT ON ITS BEHALF TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. PURSUANT TO THE BYLAWS, THE VOTING MEMBERS OF THE EXECUTIVE COMMITTEE ARE THE PRESIDENT, THE PRESIDENT-ELECT, THE CHAIR, THE PAST PRESIDENT, THE TREASURER, AND THOSE DIRECTORS SERVING THE FINAL YEAR OF THEIR PRESENT TERMS. THE CEO IS A NON-VOTING MEMBER OF THE EXECUTIVE COMMITTEE. ALL EXECUTIVE COMMITTEE MEMBERS ARE MEMBERS OF ASCO'S BOARD OF DIRECTORS. THE SCOPE OF THE EXECUTIVE COMMITTEE'S AUTHORITY IS ESTABLISHED BY ASCO'S BYLAWS, WHICH PROVIDE THAT, EXCEPT TO THE EXTENT SPECIFICALLY PROHIBITED BY RESOLUTION OF THE BOARD OF DIRECTORS OR OTHERWISE PROHIBITED BY LAW, THE EXECUTIVE COMMITTEE OF THE BOARD IS EMPOWERED TO MAKE AND IMPLEMENT MAJOR DECISIONS BETWEEN BOARD MEETINGS, AND IT MAY ACT ON ITEMS REQUIRING ACTION PRIOR TO THE NEXT ANNOUNCED BOARD OF DIRECTORS. ALL ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO THE BOARD OF DIRECTORS AT THE NEXT MEETING OF THE BOARD OF DIRECTORS IMMEDIATELY FOLLOWING THE ACTION TAKEN BY THE EXECUTIVE COMMITTEE, CONSISTENT WITH ASCO'S BYLAWS. FORM 990, PART VI, SECTION A, LINE 6: 1. FULL MEMBERS. A. 1.A. FULL MEMBERS ARE (A) EXPERIENCED LICENSED PHYSICIANS OF ANY NATION WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER (IN EXCEPTIONAL CASES, OTHER PHYSICIANS WHO HAVE MADE SIGNIFICANT CONTRIBUTIONS TO THE FIELD ARE ELIGIBLE FOR FULL MEMBER STATUS), AND (B) OTHER HEALTH PROFESSIONALS AT THE DOCTORAL LEVEL (E.G.,EPIDEMIOLOGISTS, BIOSTATISTICIANS, PUBLIC HEALTH SPECIALISTS, NURSES, OTHER SCIENTISTS, ETC.) OR INDIVIDUALS WITH EQUIVALENT ACADEMIC RANKS WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER. B. 1.B. RIGHTS OF FULL MEMBERS INCLUDE THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. 2. EMERITUS MEMBERS. A. 2.A. EMERITUS MEMBERS ARE FULL, ALLIED PHYSICIAN/DOCTORAL SCIENTIST, INTERNATIONAL CORRESPONDING AND AFFILIATED HEALTH PROFESSIONAL MEMBERS WHO HAVE REQUESTED EMERITUS STATUS AT AGE 70, UPON RETIREMENT OR EARLIER IF PERMANENTLY DISABLED. B. 2.B. EMERITUS MEMBERS WHO AT THE TIME OF THE REQUEST WERE FULL MEMBERS RETAIN THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. 3. HONORARY MEMBERS. A. 3.A. HONORARY MEMBERS ARE INDIVIDUALS WHO HAVE MADE AN OUTSTANDING CONTRIBUTION TO CLINICAL ONCOLOGY WHO ARE DESIGNATED AS AN HONORARY MEMBER BY THE BOARD OF DIRECTORS. B. 3.B. MEMBERS HAVE THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. FORM 990, PART VI, SECTION A, LINE 7A: VOTING MEMBERS OF ASCO ELECT ALL VOTING MEMBERS OF THE ASCO BOARD OF DIRECTORS. THE CATEGORIES OF MEMBERS WHO ARE ELIGIBLE TO VOTE FOR THE ELECTION OF MEMBERS OF THE GOVERNING BODY ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. FORM 990, PART VI, SECTION A, LINE 7B: ASCO'S CERTIFICATE OF INCORPORATION MAY ONLY BE AMENDED UPON THE VOTE OF THE MEMBERS ENTITLED TO VOTE, AND THE BYLAWS MAY ONLY BE AMENDED, AND DISSOLUTION OF THE CORPORATION MAY ONLY BE APPROVED WITH THE APPROVAL OF BOTH THE BOARD OF DIRECTORS AND VOTING MEMBERS OF ASCO. THE CATEGORIES OF MEMBERS WHO ARE ELIGIBLE TO VOTE ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. FORM 990, PART VI, SECTION B, LINE 11: AN ELECTRONIC COPY OF THE FINAL FORM WAS SENT, THROUGH A SECURE SITE, TO EACH MEMBER OF THE BOARD OF DIRECTORS, AND WAS REVIEWED BY THE EXECUTIVE VICE PRESIDENT & CHIEF FINANCIAL OFFICER, THE CHIEF EXECUTIVE OFFICER, AND THE EXECUTIVE VICE PRESIDENT & CHIEF OPERATING OFFICER & CHIEF LEGAL OFFICER PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C: ASCO MAINTAINS A NUMBER OF WRITTEN CONFLICTS OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL ASCO MEMBERS AND EMPLOYEES, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND CERTAIN FAMILY MEMBERS (E.G. SPOUSE, DEPENDENT CHILDREN). COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS, CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE ALSO REQUIRED TO DISCLOSE SERVICE AS AN OFFICER, DIRECTOR, OR TRUSTEE OF ANY OTHER PROFESSIONAL OR ADVOCACY ORGANIZATION RELATING TO SCIENCE OR HEALTH CARE. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE AND UPDATED ANNUALLY THEREAFTER AND WHEN ANY MATERIAL CHANGES OCCUR. ASCO'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, IF ASCO WERE TO CONTEMPLATE ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY INTERESTED PERSON (I.E. AN ASCO DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF AN ASCO COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15: COMPENSATION OF CHIEF EXECUTIVE OFFICER (CEO): THE DUTIES OF THE CEO OF ASCO INCLUDE SERVING AS: THE CEO OF ASCO, THE EXECUTIVE VICE CHAIR OF ASCO'S NON-PROFIT, 501(C)(3) TAX-EXEMPT RELATED ORGANIZATION, CONQUER CANCER FOUNDATION OF the American Society of Clinical Oncology (CC); THE CEO OF ASCO'S NON-PROFIT, 501(C)(6) TAX-EXEMPT RELATED ORGANIZATION, ASCO ASSOCIATION (D/B/A ASSOCIATION FOR CLINICAL ONCOLOGY)(ASSOCIATION), THE PRESIDENT OF QOPI CERTIFICATION PROGRAM, LLC; THE PRESIDENT OF ASCO LEASING LLC, AND THE CHAIR OF THE BOARD OF GOVERNORS OF CANCERLINQ LLC. ALL ORGANIZATIONS LISTED ARE RELATED ORGANIZATIONS OF ASCO. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE CEO AND ASCO ADDRESSES COMPENSATION OF THE CEO. THE COMPENSATION OF THE CEO WAS DETERMINED BY THE ASCO BOARD OF DIRECTORS, FOLLOWING THE REVIEW AND RECOMMENDATION OF THE BOARD COMPENSATION COMMITTEE. THE COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE CEO WAS REASONABLE. THE REVIEW, RECOMMENDATION, AND DETERMINATION OF THE CEO'S COMPENSATION BASED ON THE ABOVE-DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2019. THE COMPENSATION OF THE FOLLOWING POSITIONS WERE CONSIDERED AND APPROVED BY THE ASCO BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND AN INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE POSITIONS WAS REASONABLE. - EXECUTIVE VICE PRESIDENT & Chief Legal and Personnel Officer and ASCO Secretary (EVP & CLPO). The consideration and approval of the compensation of the EVP & CLPO based on the above described process were most recently undertaken in 2019. - EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER (EVP & CFO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CFO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2019. - EXECUTIVE VICE PRESIDENT & CHIEF MEDICAL OFFICER (EVP & CMO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CMO BASED ON THE ABOVE-DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2019. - Executive Vice President & CHIEF DIGITAL OFFICER (EVP & CDO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CDO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2019. - Executive Vice President of ASCO and CHIEF EXECUTIVE OFFICER OF THE CONQUER CANCER FOUNDATION OF the American Society of CLINICAL ONCOLOGY (EVP & CC CEO): THE EVP & CC CEO is AN EMPLOYEE OF ASCO. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CC CEO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2019. - EXECUTIVE Vice President of ASCO AND CHIEF EXECUTIVE OFFICER OF CANCERLINQ LLC (EVP & CLQ CEO): THE EVP & CLQ CEO IS AN EMPLOYEE OF ASCO. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CLQ CEO BASED ON THE ABOVE-DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2019. FORM 990, PART VI, SECTION C, LINE 18 & 19: ASCO'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S CERTIFICATE OF INCORPORATION IS ALSO AVAILABLE TO THE PUBLIC THROUGH THE SECRETARY OF STATE OF NEW YORK. ASCO'S CONFLICT OF INTEREST POLICY IS POSTED ON ASCO'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. FORM 990, PART XI, LINE 9: RELATED PARTY TRANSFER OF ASSETS $ 11,241,932 LOSS ON INTEREST RATE SWAP $ (2,851,435) -------------- TOTAL $ 8,390,497 FORM 990 PART IX LINE 11G DESCRIPTION:OTHER PROFESSIONAL FEES TOTAL FEES:18319690 FORM 990 PART IX LINE 11G DESCRIPTION:PUBLIC RELATIONS COORDINATOR TOTAL FEES:1131403 FORM 990 PART IX LINE 11G DESCRIPTION:BANK FEES TOTAL FEES:771276 ASCO LEASING LLC 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 273378225 RENTAL VA 0 0 ASCO CANCERLINQ LLC 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 472315885 QUALITY IMprv VA 28451618 15654532 ASCO CONQUER CANCER FOUNDATION OF ASCO 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 311667995 Grants VA 501(C)(3) 7 asco true ASCO ASSOCIATION 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 833561693 MEMBER SERV. VA 501(C)(6) ASCO true ASCO ASSOCIATION POLITICAL ACTION COMM 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 844213157 ADVOCACY VA 527 ASCO ASSOC false true true true true true false true false false true false true true true true true true false false ASCO Association A 294000 FMV CONQUER CANCER FOUNDATION OF ASCO B 7262500 fmv conquer cancer foundation of asco C 6418295 fmv ASCO ASSOCIATION D 5600000 fmv CONQUER CANCER FOUNDATION OF ASCO E 53745000 fmv ASCO ASSOCIATION G 11391000 fmv CONQUER CANCER FOUNDATION OF ASCO A, J 527614 fmv ASCO ASSOCIATION A, J 1180851 fmv ASCO ASSOCIATION L 252376 fmv CONQUER CANCER FOUNDATION OF ASCO N 1378424 fmv ASCO ASSOCIATION N 1930052 fmv CONQUER CANCER FOUNDATION OF ASCO O 5200875 fmv ASCO ASSOCIATION E 53745000 FMV